Aktuellt
SENASTE
Redeye endorses today’s news that Egetis has outlicensed the rights to Emcitate in Japan to Fujimoto. This move, while featuring a modest milestone value of SEK45m, grants Egetis approximately one-third of the future revenue stream. Furthermore, Fujimoto will stand for the regulatory interactions and the remaining development program, which likely will be a relatively small clinical study in Japanese patients. Given that Egetis just recently finalized a strong capital raise, it is reasonable to prioritize royalites in our view. We will return with a more extensive comment soon.
LÄS MER
